Literature DB >> 22976956

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.

Anna Dolnik1, Julia C Engelmann, Maren Scharfenberger-Schmeer, Julian Mauch, Sabine Kelkenberg-Schade, Berit Haldemann, Tamara Fries, Jan Krönke, Michael W M Kühn, Peter Paschka, Sabine Kayser, Stephan Wolf, Verena I Gaidzik, Richard F Schlenk, Frank G Rücker, Hartmut Döhner, Claudio Lottaz, Konstanze Döhner, Lars Bullinger.   

Abstract

Acute myeloid leukemia (AML) is characterized by molecular heterogeneity. As commonly altered genomic regions point to candidate genes involved in leukemogenesis, we used microarray-based comparative genomic hybridization and single nucleotide polymorphism profiling data of 391 AML cases to further narrow down genomic regions of interest. Targeted resequencing of 1000 genes located in the critical regions was performed in a representative cohort of 50 AML samples comprising all major cytogenetic subgroups. We identified 120 missense/nonsense mutations as well as 60 insertions/deletions affecting 73 different genes (∼ 3.6 tumor-specific aberrations/AML). While most of the newly identified alterations were nonrecurrent, we observed an enrichment of mutations affecting genes involved in epigenetic regulation including known candidates like TET2, TET1, DNMT3A, and DNMT1, as well as mutations in the histone methyltransferases NSD1, EZH2, and MLL3. Furthermore, we found mutations in the splicing factor SFPQ and in the nonclassic regulators of mRNA processing CTCF and RAD21. These splicing-related mutations affected 10% of AML patients in a mutually exclusive manner. In conclusion, we could identify a large number of alterations in genes involved in aberrant splicing and epigenetic regulation in genomic regions commonly altered in AML, highlighting their important role in the molecular pathogenesis of AML.

Entities:  

Mesh:

Year:  2012        PMID: 22976956     DOI: 10.1182/blood-2011-12-401471

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

Review 1.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

Review 2.  Interplay between the cancer genome and epigenome.

Authors:  Hui Shen; Peter W Laird
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Ribosomal Proteins Rpl22 and Rpl22l1 Control Morphogenesis by Regulating Pre-mRNA Splicing.

Authors:  Yong Zhang; Monique N O'Leary; Suraj Peri; Minshi Wang; Jikun Zha; Simon Melov; Dietmar J Kappes; Qing Feng; Jennifer Rhodes; Paul S Amieux; David R Morris; Brian K Kennedy; David L Wiest
Journal:  Cell Rep       Date:  2017-01-10       Impact factor: 9.423

4.  Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation.

Authors:  Fuhua Yang; Qiang Gong; Wentao Shi; Yunding Zou; Jingmin Shi; Fengjiang Wei; Qingrong Li; Jieping Chen; Wei-Dong Li
Journal:  Tumour Biol       Date:  2016-07-12

Review 5.  Genomic tools in acute myeloid leukemia: From the bench to the bedside.

Authors:  Brian S White; John F DiPersio
Journal:  Cancer       Date:  2014-01-28       Impact factor: 6.860

6.  Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.

Authors:  Michael Y Zhang; Jane E Churpek; Siobán B Keel; Tom Walsh; Ming K Lee; Keith R Loeb; Suleyman Gulsuner; Colin C Pritchard; Marilyn Sanchez-Bonilla; Jeffrey J Delrow; Ryan S Basom; Melissa Forouhar; Boglarka Gyurkocza; Bradford S Schwartz; Barbara Neistadt; Rafael Marquez; Christopher J Mariani; Scott A Coats; Inga Hofmann; R Coleman Lindsley; David A Williams; Janis L Abkowitz; Marshall S Horwitz; Mary-Claire King; Lucy A Godley; Akiko Shimamura
Journal:  Nat Genet       Date:  2015-01-12       Impact factor: 38.330

Review 7.  Cohesin mutations in myeloid malignancies made simple.

Authors:  Aaron D Viny; Ross L Levine
Journal:  Curr Opin Hematol       Date:  2018-03       Impact factor: 3.284

8.  MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.

Authors:  Velizar Shivarov; Anna Dolnik; Katharina M Lang; Jan Krönke; Florian Kuchenbauer; Peter Paschka; Verena I Gaidzik; Hartmut Döhner; Richard F Schlenk; Konstanze Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

9.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

10.  NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Authors:  Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.